233 related articles for article (PubMed ID: 11830607)
1. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.
Langer CJ; Manola J; Bernardo P; Kugler JW; Bonomi P; Cella D; Johnson DH
J Natl Cancer Inst; 2002 Feb; 94(3):173-81. PubMed ID: 11830607
[TBL] [Abstract][Full Text] [Related]
2. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
Bonomi P; Kim K; Fairclough D; Cella D; Kugler J; Rowinsky E; Jiroutek M; Johnson D
J Clin Oncol; 2000 Feb; 18(3):623-31. PubMed ID: 10653877
[TBL] [Abstract][Full Text] [Related]
3. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
4. Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience.
Johnson DH; Chang AY; Ettinger DS
Ann Oncol; 1994; 5 Suppl 6():S45-50. PubMed ID: 7865434
[TBL] [Abstract][Full Text] [Related]
5. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Belani CP; Fossella F
Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Giaccone G; Splinter TA; Debruyne C; Kho GS; Lianes P; van Zandwijk N; Pennucci MC; Scagliotti G; van Meerbeeck J; van Hoesel Q; Curran D; Sahmoud T; Postmus PE
J Clin Oncol; 1998 Jun; 16(6):2133-41. PubMed ID: 9626213
[TBL] [Abstract][Full Text] [Related]
7. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
Hensing TA; Peterman AH; Schell MJ; Lee JH; Socinski MA
Cancer; 2003 Aug; 98(4):779-88. PubMed ID: 12910523
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Li DX; Chen XB
Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
10. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.
Schild SE; Stella PJ; Geyer SM; Bonner JA; McGinnis WL; Mailliard JA; Brindle J; Jatoi A; Jett JR;
J Clin Oncol; 2003 Sep; 21(17):3201-6. PubMed ID: 12874270
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
[TBL] [Abstract][Full Text] [Related]
12. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
Klastersky J; Sculier JP; Bureau G; Libert P; Ravez P; Vandermoten G; Thiriaux J; Lecomte J; Cordier R; Dabouis G
J Clin Oncol; 1989 Aug; 7(8):1087-92. PubMed ID: 2547028
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
Kelly K; Crowley J; Bunn PA; Presant CA; Grevstad PK; Moinpour CM; Ramsey SD; Wozniak AJ; Weiss GR; Moore DF; Israel VK; Livingston RB; Gandara DR
J Clin Oncol; 2001 Jul; 19(13):3210-8. PubMed ID: 11432888
[TBL] [Abstract][Full Text] [Related]
15. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
Ramalingam SS; Dahlberg SE; Langer CJ; Gray R; Belani CP; Brahmer JR; Sandler AB; Schiller JH; Johnson DH;
J Clin Oncol; 2008 Jan; 26(1):60-5. PubMed ID: 18165641
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
[TBL] [Abstract][Full Text] [Related]
18. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Argiris A; Li Y; Murphy BA; Langer CJ; Forastiere AA
J Clin Oncol; 2004 Jan; 22(2):262-8. PubMed ID: 14722034
[TBL] [Abstract][Full Text] [Related]
19. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
20. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.
Gatzemeier U; von Pawel J; Gottfried M; ten Velde GP; Mattson K; de Marinis F; Harper P; Salvati F; Robinet G; Lucenti A; Bogaerts J; Gallant G
J Clin Oncol; 2000 Oct; 18(19):3390-9. PubMed ID: 11013280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
